Novo Nordisk CEO Steps Down Amidst Market Challenges
Tap title to read story
Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down amid declining share prices and increased competition in the obesity drug market. The company's share price has fallen over 50% since mid-2024 following disappointing trial results for new treatments. While the company maintains its current business plans, the CEO's departure reflects challenges faced in the market. A replacement is being sought, and Lars Rebien Sørensen will join the board as an observer.
Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down amid declining share prices and increased competition in the obesity drug market. The company's share price has fallen over 50% since mid-2024 following disappointing trial results for new treatments. While the company maintains its current business plans, the CEO's departure reflects challenges faced in the market. A replacement is being sought, and Lars Rebien Sørensen will join the board as an observer.
More context
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
